Giant cell arteritis

Lore & Background

Giant cell arteritis is an inflammatory autoimmune disease that primarily affects the large blood vessels, especially those around the head and neck. The cause is unknown, but the underlying mechanism involves inflammation of the small blood vessels that supply the walls of larger arteries. Symptoms may include headache, pain over the temples, flu-like symptoms, double vision, and difficulty opening the mouth. Complications can include blockage of the artery to the eye with resulting blindness, as well as aortic dissection and aortic aneurysm. The condition is frequently associated with polymyalgia rheumatica, and about half of cases co-exist with that disorder.

Diagnosis is suspected based on symptoms, blood tests, and medical imaging, and confirmed by biopsy of the temporal artery. However, in about 10% of people the temporal artery is normal. The varicella-zoster virus antigen was found in 74% of temporal artery biopsies that were GCA-positive, suggesting that the VZV infection may trigger the inflammatory cascade. Typical treatment is with high doses of steroids such as prednisone or prednisolone, tapered slowly over 12–18 months. Other medications that may be recommended include bisphosphonates to prevent bone loss and a proton-pump inhibitor to prevent stomach problems.

Giant cell arteritis is considered a medical emergency due to the potential of irreversible vision loss. Corticosteroids should be started as soon as the diagnosis is suspected, even before biopsy confirmation. Injections of tocilizumab, a humanized antibody targeting the interleukin-6 receptor, may also be used and have been found effective at minimizing recurrence and flares. Life expectancy is typically normal.

Reader's Guide

Giant cell arteritis is significant as the most common systemic vasculitis affecting adults, with a particular impact on the elderly population. Its importance lies in the potential for rapid, irreversible vision loss if not treated promptly, making it a medical emergency. The condition's association with polymyalgia rheumatica and its ability to cause aortic aneurysm and dissection underscore the need for careful monitoring. The discovery of varicella-zoster virus antigen in a majority of positive biopsies suggests a possible infectious trigger, opening avenues for further research. Treatment with corticosteroids remains the mainstay, but the introduction of tocilizumab offers an alternative for reducing recurrence and steroid-related side effects. The legacy of GCA includes improved diagnostic techniques such as high-resolution MRI and ultrasound, which can aid in non-invasive diagnosis. Despite the lack of a known cause, the condition's generally normal life expectancy with treatment highlights the effectiveness of current management strategies. Ongoing research into the inflammatory cascade, particularly the role of Th17 cells and interleukin-6, may lead to more targeted therapies.

Did You Know?

• Giant cell arteritis is the most common type of systemic vasculitis affecting adults.
• About 10% of people with giant cell arteritis have a normal temporal artery biopsy.
• Life expectancy for people with giant cell arteritis is typically normal.

The Clinical Portrait

Giant cell arteritis announces itself through a constellation of symptoms that can range from subtle to devastating. Patients commonly report persistent headaches, aching over the temples, and a general flu-like malaise. More specific warning signs include jaw claudication—pain that strikes while chewing—and tongue claudication, which in severe cases can progress to tissue necrosis. Scalp tenderness, fever, and audible bruits over the neck and shoulder arteries further paint the clinical picture. Vision is at particular risk: blurred sight, double vision, and even sudden, irreversible blindness can result when the ophthalmic artery becomes compromised, a pattern seen in roughly three-quarters of eye-involved cases. Limb claudication and difficulty opening the mouth round out the typical presentation. Because ischemic vision loss can strike without warning, clinicians treat suspected GCA as a genuine medical emergency. Relapse remains a concern, most frequently surfacing during the first year of therapy when prednisone doses fall below twenty milligrams per day, with headache and polymyalgia rheumatica serving as the most common heralds of a flare.

The Diagnostic Puzzle

Confirming a diagnosis of giant cell arteritis is rarely straightforward. Clinicians first suspect the condition from the patient's symptom profile, supported by laboratory markers such as an erythrocyte sedimentation rate exceeding sixty millimeters per hour, elevated C-reactive protein, raised alkaline phosphatase on liver function tests, and sometimes a high platelet count. Physical examination may reveal prominent, tender temporal arteries, diminished pulses across the body, ischemic changes on a fundal eye exam, or bruits over the subclavian and axillary vessels. The definitive confirmatory step remains a temporal artery biopsy, in which a one-and-a-half to three-centimeter segment is excised under local anesthesia and examined for the characteristic intimal hyperplasia, granulomatous inflammation of the media, and a CD4-positive T-cell infiltrate. Yet the disease affects vessels in a patchy distribution, meaning roughly one in ten biopsies returns a normal result. Ultrasound can display a telltale halo sign around the artery, and newer 3-tesla MRI protocols with super-high-resolution contrast imaging offer a promising non-invasive alternative, though conventional CT and standard brain MRI typically come back negative.

Treatment and the Long Taper

The cornerstone of managing giant cell arteritis is a substantial course of corticosteroids, most commonly prednisone or prednisolone, initiated at high doses to rapidly quell the inflammatory cascade. Once the patient's symptoms have cleared, the dose is reduced by approximately fifteen percent each month. As the regimen reaches a low maintenance level, the taper is deliberately slowed and stretched across the following year to minimize the risk of relapse. Because prolonged steroid use carries its own hazards, physicians typically prescribe bisphosphonates to protect against bone density loss and a proton-pump inhibitor to shield the stomach lining from acid-related complications. Beyond glucocorticoids, emerging evidence points to interleukin-6 inhibitors as an additional suppressive tool, targeting the Th17-driven inflammatory loop that perpetuates vessel damage. The underlying pathology involves dendritic cells in the arterial wall recruiting T cells and macrophages into granulomatous clusters that erode the inner and middle layers of the vessel, a process that steroids and IL-6 blockers can interrupt. Despite the demanding treatment timeline, most patients ultimately return to a normal life expectancy.

Beyond the Temples: Aortic Risk and the PMR Link

Although giant cell arteritis is best known for its effects on the head and neck, its reach extends far deeper into the vasculature. Up to sixty-seven percent of affected individuals show evidence of aortic inflammation, placing them at meaningful risk for aortic aneurysm and the potentially fatal event of aortic dissection. This has sparked ongoing debate about whether every GCA patient should undergo routine aortic imaging, with current guidance favoring a case-by-case approach guided by individual signs. The condition also shares a close bond with polymyalgia rheumatica, co-occurring in about half of all cases. PMR brings sudden pain and stiffness to the shoulders and pelvis but typically spares the cranial features—headache, jaw claudication, and visual disturbance—that define GCA, leading many experts to view the two as overlapping expressions of a single disease process. An intriguing clue comes from virology: varicella-zoster virus antigen was detected in seventy-four percent of GCA-positive temporal artery biopsies, hinting that a latent viral reactivation might help ignite the autoimmune cascade. Epidemiologically, the disease strikes roughly one in fifteen thousand people over fifty each year, peaks in the seventies, favors women, and is more prevalent among those of northern European heritage. The condition was first described in 1890.